1. Home
  2. ARL vs TVRD Comparison

ARL vs TVRD Comparison

Compare ARL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

N/A

Current Price

$16.10

Market Cap

245.7M

Sector

Real Estate

ML Signal

N/A

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$4.25

Market Cap

246.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARL
TVRD
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.7M
246.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ARL
TVRD
Price
$16.10
$4.25
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$51.67
AVG Volume (30 Days)
1.6K
114.5K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$49,060,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$42.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.43
$3.74
52 Week High
$17.00
$43.65

Technical Indicators

Market Signals
Indicator
ARL
TVRD
Relative Strength Index (RSI) 55.21 32.45
Support Level $15.26 $4.05
Resistance Level $15.98 $4.71
Average True Range (ATR) 0.22 0.27
MACD 0.05 0.50
Stochastic Oscillator 65.71 52.58

Price Performance

Historical Comparison
ARL
TVRD

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: